CIDP is generally treated with corticosteroids, PE, and IVIg - sometimes as a combination therapy.46 While clinical trial data demonstrate efficacy for all three treatment options, there is heterogeneity in the treatment response that is not well understood. For example, MMN is not responsive to either corticosteroids or PE, but responds very well to IVIg. Many immunosuppressive agents have been investigated as potential therapies for CIDP: azathioprine (probably the most commonly used in CIDP), cyclophosphamide, cyclosporin A, mycophenolate mofetil, and etanercept. It is unclear if any of these agents has a positive impact on CIDP. While clinical trial data suggest that both cyclophosphamide and cyclosporin A are beneficial, their serious side effects discourage their use. The immunomodulatory therapies, IFN-b and IFN-a, have been used to treat CIDP, however the benefit of either is unclear, and, paradoxically, IFN-a has been reported to cause CIDP. A handful of clinical trials are currently in progress; one of these is examining IFN-b, while the remainder are investigating IVIg therapy.
Was this article helpful?